刘道波,刘兴,王志强,孙铁民
LIU Dao-bo,LIU Xing,WANG Zhi-qiang,SUN Tie-min(Key Laboratory of Structure-Based Drug Design & Discovery

• 1:沈阳药科大学基于靶点的药物设计与研究教育部重点实验室

摘要(Abstract)：

目的综述三磷酸腺苷(adenosine triphosphate,ATP)合成酶抑制剂的研究进展。方法根据已报道的介绍ATP合成酶及ATP合成酶抑制剂的相关文献,将诸多ATP合成酶抑制剂按其用途分类,再按结构分相关类别具体介绍。结果 ATP合成酶广泛存在于动植物体内,其在ATP的合成和细胞间信号传导中起了重要作用,可以设计药物特异性地作用于ATP合成酶,来治疗多种疾病和调控能量代谢。结论为ATP合成酶抑制剂进一步研究提供参考。
Objective To review the recent developments in the research of adenosine triphosphate(ATP)synthase inhibitors.Methods According to references about ATP synthase and ATP synthase inhibitors,the compounds were divided into six categories and some of which were divided into sub-categories by their structures.Results ATP synthase which plays important roles in ATP synthesis and intercellular signalling was widely exist in all living organisms.Many drugs specifically acted on ATP synthase could be designed to treat various diseases and regulate energy metabolism.Conclusions This article will provide references for the further research.

关键词(KeyWords)： ATP合成酶;抑制剂;结核;肥胖;自身免疫缺陷;肿瘤;心肌缺血
ATP synthase;inhibitors;tuberculosis;obesity;autoimmune deficiency;tumor;myocardial ischemia

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 刘道波,刘兴,王志强,孙铁民
LIU Dao-bo,LIU Xing,WANG Zhi-qiang,SUN Tie-min(Key Laboratory of Structure-Based Drug Design & Discovery

DOI: 10.14066/j.cnki.cn21-1349/r.2012.11.011

参考文献(References)：

• [1]PEDERSEN P L.Transport ATPases into the year 2008:a brief overview related to types,structures,func-tions and roles in health and disease[J].J Bioenerg Biomembr,2007,39(5-6):349-355.
• [2]MOSER T L,STACK M S,ASPLIN I,et al.Angiostatin binds ATP synthase on the surface of human endotheli-al cells[J].Natl Acad Sci USA,1999,96(6):2811-2816.
• [3]BRRELLU H E,WLODARSKI B,FOSTER B J,et al.Human keratinocytes release ATP and utilize three mechanisms for nucleotide interconversion at the cell surface[J].J Biol Chem,2005,280(33):29667-29676.
• [4]KIM B W,CHOO H J,LEE J W,et al.Extracellular ATP is generated by ATP synthase complex in adipo-cyte lipid rafts[J].Exp Mol Med,2004,36(5):476-485.
• [5]PEDERSEN P L,ARNE L M.ATP Synthases[J].J Bi-ol Chem,1993,268(14):9937-9940.
• [6]KAGAWA R,MONTGOMERY M G,BRAIG K,et al.The structure of bovine F 1-ATPase inhibited by ADP and beryllium fluoride[J].EMBO J,2004,23(14):2734-2744.
• [7]NOJI H,YOSHIDA M.The Rotary Machine in the Cell,ATP Synthase[J].J Biol Chem,2001,276(3):1665-1668.
• [8]ARAKAKI N,KITA T,SHIBATA H,et al.Cell-surface H+-ATP synthase as a potential molecular target for anti-obesity drugs[J].FEBS Lett,2007,581(18):3405-3409.
• [9]BERGER K,SIVARS U,WINZELL M S,et al.Mito-chondrial ATP synthase-a possible target protein in the regulation of energy metabolism in vitro and in vivo[J].Nutr Neurosci,2002,5(3):201-210.
• [10]CHAMPAGNE E,MARTINEZ L O,COLLET X,et al.Ecto-F 1 F o-ATP synthase/F1ATPase:metabolic and immunological functions[J].Curr Opin Lipidol,2006,17(3):279-284.
• [11]KENAN D J,WAHL M L.Ectopic localization of mito-chondrial ATP synthase:a target for antiangiogenesis intervention[J].J Bioenerg Biomembr,2005,37(6):461-465.
• [12]ANDRIES K,VERHASSELT P,GUILLEMONT J,et al.A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis[J].Science,2005,307(5707):223-227.
• [13]GAURRAND S,DESJARDINS S,MEYER C,et al.Conformational analysis of R207910,a new drug candi-date for the treatment of tuberculosis,by a combined NMR and molecular modeling approach[J].Chem Biol Drug Des,2006,68(2):77-84.
• [14]GUILLEMONT J,MEYER C,PONCELET A,et al.Di-arylquinolines,synthesis pathways and quantitative structure-activity relationship studies leading to the discovery of TMC207[J].Future Medicinal Chemistry,2011,3(11):1345-1360.
• [15]HAAGSMA A C,ROODA A I,WAGNER M J,et al.Selectivity of TMC207towards mycobacterial ATP syn-thase compared with that towards the eukaryotic homo-logue antimicrob[J].Agents Chemother,2009,53(3):1290-1292.
• [16]UPADHAYAYA R S,KULKARNI G M,VASIREDDY N R,et al.Design,synthesis and biological evaluation of novel triazole,urea and thiourea derivatives of quino-line against Mycobacterium tuberculosis[J].Bioorg Med Chem,2009,13(1):4681-4692.
• [17]BLATT N B,BEDNARSKI J J,WARNER R E,et al.Benzodiazepine-induced superoxide signals B cell ap-optosis:mechanistic insight and potential therapeutic u-tility[J].J Clin Investig,2002,110(8):1123-1132.
• [18]BOITANO A,EMAL C D,LEONETTI F,et al.Struc-ture activity studies of a novel cytotoxic benzodiazepine[J].Bioorg Med Chem Lett,2003,13(19):3327-3330.
• [19]DAS B,MONDRAGON M O,SADEGHIAN M,et al.A novel ligand in lymphocyte-mediated cytotoxicity:ex-pression of theβ-subunit of H+-transporting ATP syn-thase on the surface of tumor cell lines[J].J Exp Med,1994,180(1):273-281.
• [20]MARTINEZ L O,JACQUET S,ESTEVE J P,et al.Ec-topicβ-chain of ATP synthase is an apolipoprotein AI receptor in hepatic HDL endocytosis[J].Nature,2003,421(6918):75-79.
• [21]ZHENG J,RAMIREZ V D.Inhibition of mitochondrial proton F 1 F o-ATPase/ATP synthase by polyphenolic phytochemicals[J].Br J Pharmacol,2000,130(5):1115-1123.
• [22]GLEDHILL J R,MONTGOMERY M G,LESLIE A G,et al.Mechanism of inhibition of bovine F 1-ATPase by resveratrol and related polyphenols[J].Proc Natl Acad Sci USA,2007,104(34):13632-13637.
• [23]EBEL R E,LARDY H A.Influence of aurovertin on mitochondrial ATPase activity[J].J Biol Chem,1975,250(13):4992-4995.
• [24]ECKHARDT U,HANSTEIN W G.Beef heart mito-chondrial F 1-ATPase:inhibition by azidoadenyl-5'-yl imidodiphosphates and cooperative binding of substrate[J].Biochim Biophys Acta,1993,144(3):419-425.
• [25]ISSARTEL J P,KLEIN G,SATRE M,et al.Aurovertin binding sites on beef heart mitochondrial F 1-ATPase.Study with[14C]aurovertin D of the binding stoichiom-etry and of the interaction between aurovertin and the natural ATPase inhibitor for binding to F1[J].Bio-chemistry,1983,22(14):3492-3497.
• [26]RAAIJ M J,ABRAHAMS J P,LESLIE A G,et al.The structure of bovine F 1-ATPase complexed with the anti-biotic inhibitor aurovertin B[J].Proc Natl Acad Sci USA,1996,93(14):6913-6917.
• [27]LEE R S,PAGAN J,SATRE M,et al.Identification of a mutation in Escherichia coli F 1-ATPaseβ-subunit conferring resistance to aurovertin[J].FEBS Lett,1989,253(1-2):269-272.
• [28]PENEFSKY H S.Reversible binding of Pi by beef heart mitochondrial adenosine triphosphatase[J].J Bi-ol Chem,1977,252(9):2891-2899.
• [29]LINNETT P E,BEECHEY R B.Inhibitors of the ATP synthase system[J].Methods Enzymol,1979,55(59):472-518.
• [30]HUANG T C,CHANG H Y,HSU C H,et al.Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B[J].J Proteome Res,2008,7(4):1433-1444.
• [31]KIM J W,ADACHI H,SHIN-YA K,et al.Apoptolidin,a new apoptosis inducer in transformed cells from No-cardiopsis sp[J].J Antibiot Tokyo,1997,50(7):628-630.
• [32]SALOMON A R,VOEHRINGER D W,HERZENBERG L A,et al.Apoptolidin,a selective cytotoxic agent,is an inhibitor of F 1 F o-ATPase[J].Chemistry Biology,2001,8(1):71-80.
• [33]WARBURG O.On the origin of cancer cells[J].Sci-ence,1956,123(3191):309-314.
• [34]SALOMON A R,VOEHRINGER D,HERZENBERG L,et al.Understanding and exploiting the mechanistic basis for selectivity of polyketide inhibitors of F 1 F o-ATPase[J].Proc Natl Acad Sci USA,2000,97(26):14766-1477l.
• [35]ROBERTS H,CHOO W M,MURPHY M,et al.mit-Mutations in the oli2region of mitochondrial DNA afecting the20,000dalton subunit of the mitochondrial ATPase in Saccharomyces cerevisiae[J].FEBS Lett,1979,108(2):501-504.
• [36]DROSE S,ALTENDORF K.Bafilomycins and concana-mycins as inhibitors of V-ATPases and P-ATPases[J].J Exp Biol,1997,200(1):1-8.
• [37]JOHN U P,NAGLEY P.Amino acid substitutions in mitochondrial ATPase subunit6of Saccharomyces cer-evisiae leading to oligomycin resistance[J].FEBS Lett,1986,207(1):79-83.
• [38]KIRST H A,MYNDERSE J S,MARTIN J W,et al.Structure of the spiroketal-macrolide ossamycin[J].J Antibiot Tokyo,1996,49(2):162-167.
• [39]GRIFFITHS D E,HOUGHTON R L.Studies on energy-linked reactions:modified mitochondrial ATPase of oli-gomycin-resistant mutants of Saccharomyces cerevisiae[J].Eur J Biochem,1974,46(2):157-167.
• [40]PERLIN D S,LATCHNEY L R,SENIOR A E.Inhibi-tion of Escherichia coli H+-ATPase by venturicidin,ol-igomycin and ossamycin[A].Biochim Biophys Acta,1985,807(3):238-244.
• [41]GALANIS M,MATTOON J R,NAGLEY P.Amino acid substitutions in mitochondrial ATP synthase subunit9 of Saccharomyces cerevisiae leading to venturicidin or ossamycin resistance[J].FEBS Lett,1989,249(2):333-336.
• [42]SALOMON A R,ZHANG Y,SETO H.Structure-activ-ity relationships within a family of selectively cytotoxic macrolide natural products[J].Org Lett,2001,3(1):57-59.
• [43]KOMI Y,OHNO O,SUZUKI Y,et al.Inhibition of tumor angiogenesis by targeting endothelial surface ATP synthase with sangivamycin.Jpn J Clin Oncol,2007,37(11):867-873.
• [44]ARAKAKI N,NAGAO T,NIKI R,et al.Possible role of cell surface H+-ATP synthase in the extracellular ATP synthase and proliferation of human umbilical vein endothelial cells[J].Mol Cancer Res,2003,1(13):931-939.
• [45]DADI P K,AHMAD M,AHMAD Z.Inhibition of AT-Pase activity of Escherichia coli ATP synthase by poly-phenols[J].Inter Jour of Biol Macr,2009,45(1):72-79.
• [46]ABAD M C,ARNI R K,GRELLA D K,et al.The X-ray crystallographic structure of the angiogenesis inhib-itor angiostatin[J].J Mol Biol,2002,318(4):1009-1017.
• [47]MOSER T L,KENAN D J,ASHLEY T A,et al.Endo-thelial cell surface F 1 F o-ATP synthase is active in ATP synthesis and is inhibited by angiostatin[J].Proc Natl Acad Sci USA,2001,98(12):6656-6661.
• [48]DUCHEN M R.Mitochondria in health and disease:perspectives on a new mitochondrial biology[M].Mo-lecular Aspects of Medicine,2004,25(4):365-451.
• [49]ROUSLIN W,BROGE C W.Regulation of the mito-chondrial adenosine5'-triphosphatase in situ during is-chemia and in vitro in intact and sonicated mitochon-dria from slow and fast heart rate species[J].Arch Biochem Biophys,1990,280(1):103-111.
• [50]GROVER G J,MARONE P A,KOETZNER L,et al.Energetic signalling in the control of mitochondrial F1Fo ATP synthase activity in health and disease[J].The International Journal of Biochemistry&Cell Biolo-gy,2008,40(12):2698-2701.
• [51]GREEN D W,GROVER G J.The IF1protein inhibitor protein of the mitochondrial F1Fo ATPase[J].Bio-chimica Biophysica Acta,2000,1458(2-3):343-355.
• [52]VAN RAAIJ,ORRISS G L,MONTGOMERY M G,et al.The ATPase inhibitor protein from bovine heart mi-tochondria:the minimal inhibitory sequence[M].Biochemistry,1996,35(49):15618-15625.
• [53]CABEZON E,MONTGOMERY M G,LESLIE A G,et al.The structure of bovine F 1-ATPase in complex with its regulatory protein IF1[J].Nat Struct Biol,2003,10(9):744-750.
• [54]GLEDHILL J R,MONTGOMERY M G,LESLIE A G,et al.How the regulatory protein,IF1,inhibits F 1-AT-Pase from bovine mitochondria[J].Proc Natl Acad Sci USA,2007,104(40):15671-15676.
• [55]HAMANN L G,DING C Z,MILLER A V,et al.Benzo-diazepine-based selective inhibitors of mitochondrial F 1 F o-ATP hydrolase[J].Bioorg Med Chem Lett,2004,14(4):1031-1034.
• [56]ATWAL K S,WANG P,ROGERS W L,et al.Small molecule mitochondrial F 1 F o-ATPase hydrolase inhibi-tors as cardioprotective agents.Identification of4-(N-arylimidazole)-substituted benzopyran derivatives as selective hydrolase inhibitors[J].J Med Chem,2004,47(5):1081-1084.
• [57]GROVER G J,ATWAL K S,SLEPH P G,et al.Exces-sive ATP hydrolysis in ischemic myocardium by mito-chondrial F 1 F o-ATPase:effect of selective pharmaco-logical inhibition of mitochondrial ATPase hydrolase activity[J].Am J Physiol Heart Circ Physiol,2004,287(4):1747-1755.
• [58]ATWAL K S,AHMAD S,DING C Z,et al.N-[1-Aryl-2-(1-imidazolo)ethyl]-guanidine derivatives as potent inhibitors of the bovine mitochondrial F 1 F o-ATP hydro-lase[J].Bioorg Med Chem Lett,2004,14(4):1027-1030.
• [59]PINET E,NEUMANN J M,DAHSE I,et al.Multiple interconverting conformers of the cyclic tetrapeptide tentoxin,[cyclo-(L-MeAla1-L-Leu2-MePhe[(Z)△]3-Gly4)],as seen by two-dimensional 1 H-NMR spec-troscopy[C].Biopolymers,1995,36(2):135-152.
• [60]STEELE J A,UCHYTIL T F,DURBIN R D,et al.Chloroplast coupling factor1:a species-specific recep-tor for tentoxin[J].Proc Natl Acad Sci USA,1976,73(7):2245-2248.
• [61]SIGALAT C,PITARD B,HARAUX F.Proton coupling is preserved in membrane-bound chloroplast ATPase activated by high concentrations of tentoxin[J].FEBS Lett,1995,368(2):253-256.
• [62]GROTH G,POHL E.The structure of the chloroplast F 1-ATPase at3.2resolution[J].J Biol Chem,2001,276(2):1345-1352.
• [63]PINET E,CAVELIER F,VERDUCCI J,et al.Synthe-sis,structure,and properties of MeSer1-tentoxin,a new cyclic tetrapeptide which interacts specifically with chloroplast F 1-H+-ATPase differentiation of inhibitory and stimulating effects[C].Biochemistry,1996,35(39):12804-12811.
• [64]SANTOLINI J,MINOLETTI C,GOMIS J M,et al.An insight into the mechanism of inhibition and reactiva-tion of the F 1-ATPases by tentoxin[C].Biochemistry,2002,41(19):6008-6018.
• [65]CAVELIER F,ENJALBAL C,SANTOLINI J,et al.An-alogs of tentoxin:tools for mechanistic investigations[J].Lett Peptide Sci,1997,4(4/6):283-288.